256 related articles for article (PubMed ID: 34635731)
1. Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Lee YS; Lee JC; Kim JH; Kim J; Hwang JH
Sci Rep; 2021 Oct; 11(1):20152. PubMed ID: 34635731
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S
Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981
[TBL] [Abstract][Full Text] [Related]
3. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH
Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z
BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Arima S; Kawahira M; Shimokawa M; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Mitsugi K; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Otsuka T
Pancreas; 2021 Aug; 50(7):957-964. PubMed ID: 34347735
[TBL] [Abstract][Full Text] [Related]
6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
7. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
[TBL] [Abstract][Full Text] [Related]
8. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
[TBL] [Abstract][Full Text] [Related]
9. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Mie T; Sasaki T; Takeda T; Fukuda K; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Pancreas; 2021 Apr; 50(4):595-601. PubMed ID: 33939674
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Cui J; Zhang X; Qu S; Wang L
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):691-697. PubMed ID: 32976031
[TBL] [Abstract][Full Text] [Related]
13. First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
Hatashima A; Arango MJ; Reardon J; Freeman T; Williams T; McLaughlin EM; Abushahin L
Future Oncol; 2022 Jun; 18(20):2521-2532. PubMed ID: 35579260
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Dong LP; Liu YM; Lu WJ; Tang KZ
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(17):6316-6327. PubMed ID: 36111933
[TBL] [Abstract][Full Text] [Related]
16. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
[TBL] [Abstract][Full Text] [Related]
17. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
18. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
19. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Kang J; Hwang I; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Hong SM; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Aug; 36(4):732-741. PubMed ID: 29616439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]